Pharmaceuticals Market Research Reports & Industry Analysis

Publications found: 36,694

Sort by:

Cardiovascular Drugs: Global Markets to 2022

US$ 2,750.00

... report provides detailed exposure of the cardiovascular drugs market, highlighting major cardiovascular diseases with detailed epidemiology for the ... pipeline assessment section. Cardiovascular drug delivery systems are also included in the report, such as nanoparticle-mediated drug delivery, gene therapy and ...

March 2018 174 pages

Drugs for Rheumatoid Arthritis: Global Markets to 2022

US$ 2,750.00

... Includes: 95 data tables An overview of the global rheumatoid arthritis drugs market Analyses of global market trends, with data from 2016 and 2017, and projections ... potential and their future applications Explanation of major drivers and regional dynamics of the market and current trends within the industry ...

March 2018 182 pages

Europe Over the Counter Drugs Market - Forecasts from 2018 to 2023

US$ 3,000.00

Europe over-the-counter (OTC) drugs market is projected to witness a compound annual ... 2023 from US$26.486 billion in 2017. Rising pharmaceutical (OTC drug) spending in European countries as an affordable treatment option is ... of the key stakeholders in the Europe OTC Drug value chain. Last step involves complete ...

March 2018 82 pages

Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Botox Market 2018 Forecast to 2023

US$ 4,880.00

... : This report focuses on the Botox in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report ... LIBP Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) ...

March 2018 108 pages

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Pipeline Review, H1 2018

US$ 3,500.00

... Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

March 2018 81 pages

Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

US$ 2,400.00

... location. “Global Tumor Necrosis Factor Inhibitors Drug Market Dosage Price & Clinical Pipeline Outlook 2024” Report Highlights: Global TNF Inhibitors Market Trends Key TNF Inhibitors Drug Sales, Price & Dosage Analysis Global TNF Inhibitors Clinical Pipeline by Company ...

March 2018 300 pages

Global Diffuse Large B Cell Lymphoma Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

US$ 2,400.00

... Drugs Market Analysis of Diffuse Large B Cell Lymphoma Market Sales Opportunity till 2024 Global Diffuse Large B Cell Lymphoma Clinical Pipeline: 84 Drugs Marketed Global Diffuse Large B Cell Lymphoma Clinical Insight Hematological Cancers are the most fatal types of cancer as they affect the blood cells ...

March 2018 280 pages

Global Radioimmunotherapy Market, Dosage, Price & Clinical Pipeline Outlook 2022

US$ 2,400.00

... of Radioimmunotherapy Clinical Status of Radioimmunotherapy in Various Cancer Therapy Emerging Opportunities in the Radioimmunotherapy Segment Patent, Dosage & Price Analysis Antibodies in Radioimmunotherapy Global Radioimmunotherapy Clinical Pipeline: 68 Drugs Clinical Pipeline analysis by Phase Cancer ...

March 2018 200 pages

Global GABA Receptor Agonist Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

US$ 2,200.00

... : Global GABA Drugs Market Analysis by Dosage & Price Promising GABA Receptor Agonist Therapeutics Trends and Market Dynamics of GABA Receptor Agonist Global GABA Receptor Agonists Clinical Pipeline = 49 Drugs Marketed Global GABA Receptor Agonists Clinical Insight = 28 Drugs GABA Receptor Agonist Market ...

March 2018 220 pages

Global Metastatic Cancer Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

US$ 3,000.00

... . Metastatic cancer therapy market is further segmented into each type of metastatic cancer such as lung cancer, breast cancer, prostate cancer, brain tumor and several others which are the most common types of cancers globally ...

March 2018 330 pages

Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024

US$ 2,600.00

... enhance the Global Dendritic cell vaccine market. Dendritic cell vaccine is the fastest growing segment of cancer vaccine market with other classes of vaccine like peptide vaccines, HPV vaccine, HBV vaccines etc. Dendritic cell vaccines are more ...

March 2018 255 pages

Pediatric Drugs and Vaccines: Market Research Report

US$ 5,600.00

... markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs, and Other Pediatric Drugs. The Pediatric Vaccines market ... is provided for these markets. Market data and analytics are ...

February 2018 431 pages

RFID in Healthcare: Market Research Report

US$ 5,450.00

This report analyzes the worldwide markets for RFID in Healthcare in US$ Thousand. The report provides ... -year historic analysis is provided for these markets. Market data and analytics are derived from primary ... niche players such as - Dolphin RFID Pvt. Ltd. GAO RFID, Inc. GE Healthcare Grifols, S.A Impinj, Inc.

February 2018 242 pages

North America and Europe Gene Synthesis Market by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 4,480.00

... Scope of the Report: This report focuses on the Gene Synthesis in North America and Europe market, especially in United States, United Kingdom, ... 19 Chapters to deeply display the North America and Europe Gene Synthesis market. Chapter 1, to describe Gene Synthesis Introduction, product type and application ...

February 2018 105 pages

Global Opioids Drugs Market Report 2018

US$ 2,350.00

... still maintained a relatively optimistic growth, the past four years, Opioids Drugs market size to maintain the average annual growth rate of X% from ... in the next few years, Opioids Drugs market size will be further expanded, we expect that by 2022, The market size of the Opioids Drugs will reach XXXX million ...

February 2018 115 pages

Global Pharmaceutical Grade Fulvic Acid Market Report 2018

US$ 2,350.00

... ) Section (5 6 7): 500 USD—— Product Type Segmentation (High Purity Pharmaceutical Grade Fulvic Acid, Low Purity Pharmaceutical Grade Fulvic Acid) Industry Segmentation (Medicine, Health Care Products, Others) Channel ...

February 2018 123 pages

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) – Pipeline Review, H1 2018

US$ 3,500.00

... Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 90 pages

MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) – Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) development landscape Develop and design ...

February 2018 37 pages

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development ...

February 2018 120 pages

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H1 2018

US$ 3,500.00

... DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 25 pages

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023

US$ 2,000.00

... report titled “Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023” presents the market potential of six major pipeline drugs meant for ...

February 2018 120 pages

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 77 pages

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... also reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics development with ...

February 2018 65 pages

Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division Protein Kinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC 2.7.11.22 or EC 2.7.11.23) development ...

February 2018 49 pages

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H1 2018

US$ 3,500.00

... Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 63 pages

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) development landscape Develop and design ...

February 2018 110 pages

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H1 2018

US$ 3,500.00

... key players involved in Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) targeted therapeutics development ...

February 2018 60 pages

Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) - Pipeline Review, H1 2018

US$ 3,500.00

... . It also reviews key players involved in Glutamate Carboxypeptidase 2 (Folate Hydrolase 1 or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly Gamma Glutamate Carboxypeptidase or Cell Growth Inhibiting Gene 27 Protein or FOLH1 or EC 3.4.17.21) targeted therapeutics development with respective active ...

February 2018 38 pages

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) development ...

February 2018 51 pages

Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) - Pipeline Review, H1 2018

US$ 3,500.00

... key players involved in Mitogen Activated Protein Kinase 3 (ERT2 or Insulin Stimulated MAP2 Kinase or Extracellular Signal Regulated Kinase 1 or MAP Kinase Isoform p44 or Microtubule Associated Protein 2 Kinase or p44 ERK1 or MAPK3 or EC 2.7.11.24) targeted therapeutics development with respective active ...

February 2018 45 pages

Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) development landscape Develop ...

February 2018 58 pages

RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) development landscape Develop and ...

February 2018 52 pages

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 55 pages

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) development landscape Develop ...

February 2018 62 pages

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H1 2018

US$ 3,500.00

... Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 74 pages

North America and Europe Botox Market by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 4,480.00

... . Scope of the Report: This report focuses on the Botox in North America and Europe market, especially in United States, United Kingdom, Canada, ... There are 19 Chapters to deeply display the North America and Europe Botox market. Chapter 1, to describe Botox Introduction, product type and application, market ...

February 2018 108 pages

North America and Europe Active Pharmaceutical Ingredients Market by Manufacturers, Regions, Type and Application, Forecast to 2023

US$ 4,480.00

... the Report: This report focuses on the Active Pharmaceutical Ingredients in North America and Europe market, especially in United States, United ... to deeply display the North America and Europe Active Pharmaceutical Ingredients market. Chapter 1, to describe Active Pharmaceutical Ingredients Introduction, ...

February 2018 103 pages

Visceral Pain - Pipeline Review, H1 2018

US$ 2,000.00

... . The Visceral Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

February 2018 51 pages

Trigeminal Neuralgia - Pipeline Review, H1 2018

US$ 2,000.00

... . The Trigeminal Neuralgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Trigeminal Neuralgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

February 2018 54 pages

C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) development landscape Develop ...

February 2018 60 pages

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H1 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape Develop and design ...

February 2018 113 pages

Bacillary Dysentery (Shigellosis) - Pipeline Review, H1 2018

US$ 2,000.00

... . The Bacillary Dysentery (Shigellosis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacillary Dysentery (Shigellosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

February 2018 43 pages

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H1 2018

US$ 3,500.00

... also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with ...

February 2018 104 pages

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H1 2018

US$ 3,500.00

... Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 59 pages

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H1 2018

US$ 3,500.00

... Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 120 pages

Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Inhibitor of Nuclear Factor Kappa B Kinase Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kinase Beta or I Kappa B Kinase 2 or IKBKB or EC 2.7.11.10) development landscape Develop ...

February 2018 40 pages

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Pipeline Review, H1 2018

US$ 3,500.00

... Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 51 pages

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Review, H1 2018

US$ 3,500.00

... reviews Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 49 pages

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H1 2018

US$ 3,500.00

... Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 55 pages

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H1 2018

US$ 3,500.00

... Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

February 2018 46 pages

Filters

Clear all

Price

—

Date

—

Pages

—

Offers

Discount Offer from GMD Research

Special Offer from MP Advisors

Special Offer on Therapy Class R...